Premium
Silencing of high‐mobility group box 2 (HMGB2) modulates cisplatin and 5‐fluorouracil sensitivity in head and neck squamous cell carcinoma
Author(s) -
Syed Nazia,
Chavan Sandip,
Sahasrabuddhe Nandini A.,
Renuse Santosh,
Sathe Gajanan,
Nanjappa Vishalakshi,
Radhakrishnan Aneesha,
Raja Remya,
Pinto Sneha M.,
Srinivasan Anand,
Prasad T. S. Keshava,
Srikumar Kotteazeth,
Gowda Harsha,
Santosh Vani,
Sidransky David,
Califano Joseph A.,
Pandey Akhilesh,
Chatterjee Aditi
Publication year - 2015
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201400338
Subject(s) - fluorouracil , cisplatin , gene silencing , head and neck squamous cell carcinoma , basal cell , cancer research , head and neck , oncology , medicine , head and neck cancer , biology , chemotherapy , cancer , genetics , gene , surgery
Dysregulation of protein expression is associated with most diseases including cancer. MS-based proteomic analysis is widely employed as a tool to study protein dysregulation in cancers. Proteins that are differentially expressed in head and neck squamous cell carcinoma (HNSCC) cell lines compared to the normal oral cell line could serve as biomarkers for patient stratification. To understand the proteomic complexity in HNSCC, we carried out iTRAQ-based MS analysis on a panel of HNSCC cell lines in addition to a normal oral keratinocyte cell line. LC-MS/MS analysis of total proteome of the HNSCC cell lines led to the identification of 3263 proteins, of which 185 proteins were overexpressed and 190 proteins were downregulated more than twofold in at least two of the three HNSCC cell lines studied. Among the overexpressed proteins, 23 proteins were related to DNA replication and repair. These included high-mobility group box 2 (HMGB2) protein, which was overexpressed in all three HNSCC lines studied. Overexpression of HMGB2 has been reported in various cancers, yet its role in HNSCC remains unclear. Immunohistochemical labeling of HMGB2 in a panel of HNSCC tumors using tissue microarrays revealed overexpression in 77% (54 of 70) of tumors. The HMGB proteins are known to bind to DNA structure resulting from cisplatin-DNA adducts and affect the chemosensitivity of cells. We observed that siRNA-mediated silencing of HMGB2 increased the sensitivity of the HNSCC cell lines to cisplatin and 5-FU. We hypothesize that targeting HMGB2 could enhance the efficacy of existing chemotherapeutic regimens for treatment of HNSCC. All MS data have been deposited in the ProteomeXchange with identifier PXD000737 (http://proteomecentral.proteomexchange.org/dataset/PXD000737).